Literature DB >> 10693987

p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer.

K Angelopoulou1, H Yu, B Bharaj, M Giai, E P Diamandis.   

Abstract

OBJECTIVES: Autoantibodies against the p53 tumor suppressor protein have been detected in the serum of a proportion of patients with various cancers. The generation of such antibodies has been proposed to be due to either tumor p53 protein accumulation or to the type of p53 gene mutation. These hypotheses are examined in the present study. DESIGN AND METHODS: Using immunofluorometric assays, we studied 195 patients with primary breast cancer for the presence of p53 antibodies in serum and p53 protein accumulation in the corresponding tumor. Seventeen patients (9%) were p53 antibody-positive and 77 (40%) overexpressed p53. Ten of the 17 p53 antibody-positive patients had tumor p53 accumulation and 7 were negative for p53. Statistical analysis revealed a weak association between the presence of p53 antibodies and p53 protein accumulation (p = 0.05). Direct DNA sequencing of exons 1-11 of the p53 gene was performed for 16 p53 antibody-positive and 16 p53 antibody-negative patients.
RESULTS: Five of the seropositive and eight of the seronegative patients had a p53 gene mutation. Four of the five mutations in the p53 antibody-positive patients affected a Tyr residue, whereas none of the gene abnormalities in the seronegative patients had such an effect.
CONCLUSIONS: We conclude that p53 antibodies tend to develop in patients with tumor p53 accumulation, but p53 accumulation is neither sufficient nor necessary for the generation of the immune response. Further, p53 antibody-positive patients do not have higher frequency of p53 gene mutations than p53 antibody-negative patients, but the former patient group is associated with a Tyr substitution in the protein product.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10693987     DOI: 10.1016/s0009-9120(99)00084-3

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.

Authors:  Douglas D Taylor; Cicek Gercel-Taylor; Lynn P Parker
Journal:  Gynecol Oncol       Date:  2009-07-31       Impact factor: 5.482

2.  Autoantibodies against p53 are associated with chromosome 17p deletions in chronic lymphocytic leukemia.

Authors:  Bradley T Messmer; Talia S Nour-Omid; Emanuela Ghia; Ana B Sanchez; Thomas J Kipps
Journal:  Leuk Res       Date:  2011-05-12       Impact factor: 3.156

Review 3.  The sentinel within: exploiting the immune system for cancer biomarkers.

Authors:  Karen S Anderson; Joshua LaBaer
Journal:  J Proteome Res       Date:  2005 Jul-Aug       Impact factor: 4.466

4.  p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer.

Authors:  Karen S Anderson; Jessica Wong; Allison Vitonis; Christopher P Crum; Patrick M Sluss; Joshua Labaer; Daniel Cramer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

5.  Autoimmunity to the M(r) 32,000 subunit of replication protein A in breast cancer.

Authors:  J E Tomkiel; H Alansari; N Tang; J B Virgin; X Yang; P VandeVord; R L Karvonen; J L Granda; M J Kraut; J F Ensley; F Fernández-Madrid
Journal:  Clin Cancer Res       Date:  2002-03       Impact factor: 12.531

Review 6.  Antigen-specific immunotherapy of cervical and ovarian cancer.

Authors:  Chien-Fu Hung; T C Wu; Archana Monie; Richard Roden
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

7.  Protein biomarkers for the early detection of breast cancer.

Authors:  David E Misek; Evelyn H Kim
Journal:  Int J Proteomics       Date:  2011-08-11

8.  Simplified approaches for the development of an ELISA to detect circulating autoantibodies to p53 in cancer patients.

Authors:  Ratchada Cressey; Saranya Pimpa; Busyamas Chewaskulyong; Nirush Lertprasertsuke; Somchareon Saeteng; Chatchai Tayapiwatana; Watchara Kasinrerk
Journal:  BMC Biotechnol       Date:  2008-02-20       Impact factor: 2.563

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.